WMA
ABUS icon

Wealth Management Associates’s Arbutus Biopharma ABUS Stock Holding History

Wealth Management Associates’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$593K Buy
131,870
+4,000
+3% +$17.5K 0.2% 100
2025
Q4 		$615K Buy
127,870
+15,050
+13% +$67.7K 0.21% 89
2025
Q3 		$512K Buy
112,820
+7,900
+8% +$29K 0.18% 102
2025
Q2 		$324K Buy
104,920
+8,500
+9% +$28.2K 0.13% 147
2025
Q1 		$337K Buy
96,420
+35,400
+58% +$118K 0.14% 133
2024
Q4 		$200K Buy
61,020
+6,500
+12% +$23.9K 0.09% 199
2024
Q3 		$210K Buy
54,520
+4,700
+9% +$18K 0.09% 195
2024
Q2 		$154K Hold
49,820
– – 0.07% 196
2024
Q1 		$154K Buy
49,820
+1,800
+4% +$4.66K 0.07% 196
2023
Q4 		$120K Sell
48,020
-6,600
-12% -$12.9K 0.06% 195
2023
Q3 		$111K Buy
54,620
+5,000
+10% +$10.5K 0.06% 186
2023
Q2 		$114K Hold
49,620
– – 0.06% 185
2023
Q1 		$150K Buy
49,620
+350
+0.7% +$987 0.09% 185
2022
Q4 		$115K Buy
49,270
+8,400
+21% +$20.1K 0.08% 181
2022
Q3 		$78.1K Buy
40,870
+11,200
+38% +$26.4K 0.06% 172
2022
Q2 		$80.4K Buy
29,670
+7,500
+34% +$19.2K 0.05% 173
2022
Q1 		$66.1K Buy
22,170
+3,600
+19% +$11K 0.04% 186
2021
Q4 		$72.2K Buy
18,570
+1,800
+11% +$6.99K 0.04% 195
2021
Q3 		$71.9K Sell
16,770
-700
-4% -$2.33K 0.04% 192
2021
Q2 		$52.9K Sell
17,470
-11,700
-40% -$36.2K 0.03% 197
2021
Q1 		$97.1K Sell
29,170
-2,400
-8% -$9.26K 0.06% 186
2020
Q4 		$112K Buy
+31,570
New +$111K 0.07% 177

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Wealth Management Associates's ABUS Position: Q1 2026 in Review

Wealth Management Associates increased its Arbutus Biopharma (ABUS) stake by 3.1% in Q1 2026, buying an estimated $17.5K and bringing the position to 131,870 shares worth $593K. The position accounts for 0.2% of the portfolio, ranked #100.

Wealth Management Associates first reported a position in ABUS in Q4 2020 and has held it in 22 quarters since. The position peaked at $615K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Wealth Management Associates held 131,870 shares of Arbutus Biopharma worth $593K as of Q1 2026.
  • Wealth Management Associates bought 4,000 Arbutus Biopharma shares in Q1 2026, an estimated $17.5K.
  • Arbutus Biopharma made up 0.2% of Wealth Management Associates's portfolio in Q1 2026, its #100 holding.
  • Wealth Management Associates first reported a position in Arbutus Biopharma in Q4 2020 and has held it in 22 quarters since.
  • Wealth Management Associates's Arbutus Biopharma position peaked at $615K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Wealth Management Associates's 13F filing for Q1 2026, filed 13 May 2026.